Home Cart Sign in  
Chemical Structure| 2137030-98-7 Chemical Structure| 2137030-98-7

Structure of Ensartinib 2HCl
CAS No.: 2137030-98-7

Chemical Structure| 2137030-98-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ensartinib 2HCl is a dual ALK/MET inhibitor with high anti-tumor activity, suitable for research on the treatment of various tumors.

Synonyms: X-396 dihydrochloride; Ensartinib dihydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ensartinib 2HCl

CAS No. :2137030-98-7
Formula : C26H28Cl3FN6O3
M.W : 597.90
SMILES Code : ClC1=C(C(Cl)=CC=C1F)[C@@H](C)OC2=C(N)N=NC(C(NC3=CC=C(C=C3)C(N4C[C@H](C)N[C@H](C)C4)=O)=O)=C2.Cl
Synonyms :
X-396 dihydrochloride; Ensartinib dihydrochloride
MDL No. :MFCD31657344

Safety of Ensartinib 2HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of Ensartinib 2HCl

RTK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
KB-V1 5.86 ± 1.17 µM 72 hours Evaluate the cytotoxicity of Ensartinib on KB-V1 cells Cancers (Basel). 2022 May 9;14(9):2341.
NIH 3T3 cells 24.3 nM 72 hours Evaluate the inhibitory effect of Ensartinib on different ALK fusion variants, KIF5B-ALK was highly sensitive to ensartinib Mol Cancer Ther. 2021 Nov;20(11):2189-2197.
Ba/F3 cells 57 nmol/L 3 days To evaluate the inhibitory effect of Ensartinib on TRK, results showed that the IC50 of Ensartinib for wild-type fusion cells was 57 nmol/L, while it had no inhibitory effect on solvent-front mutation cells, indicating high target specificity. Cancer Commun (Lond). 2021 Feb;41(2):192-196.
HL-7702 cells 0, 1, 2, 4 μM 36 hours To evaluate the effect of Ensartinib on the survival rate and apoptosis of HL-7702 cells. Results showed that Ensartinib reduced cell survival rate and induced apoptosis in a concentration-dependent manner. Cell Biol Toxicol. 2024 May 24;40(1):38.
NIH 3T3 cells 24.3 nM 72 hours Evaluate the inhibitory effect of Ensartinib on different ALK fusion variants, KIF5B-ALK was highly sensitive to ensartinib Mol Cancer Res. 2018 Nov;16(11):1724-1736.
MDR19-HEK293 4.42 ± 0.66 µM 72 hours Evaluate the cytotoxicity of Ensartinib on MDR19-HEK293 cells Cancers (Basel). 2022 May 9;14(9):2341.
PcDNA3.1-HEK293 1.30 ± 0.14 µM 72 hours Evaluate the cytotoxicity of Ensartinib on pcDNA3.1-HEK293 cells Cancers (Basel). 2022 May 9;14(9):2341.
NCI-ADR-RES 9.20 ± 2.42 µM 72 hours Evaluate the cytotoxicity of Ensartinib on NCI-ADR-RES cells Cancers (Basel). 2022 May 9;14(9):2341.
OVCAR-8 3.00 ± 0.57 µM 72 hours Evaluate the cytotoxicity of Ensartinib on OVCAR-8 cells Cancers (Basel). 2022 May 9;14(9):2341.
KB-3-1 0.92 ± 0.19 µM 72 hours Evaluate the cytotoxicity of Ensartinib on KB-3-1 cells Cancers (Basel). 2022 May 9;14(9):2341.
HepG2-CYP3A4 23.5 µM 10 min Evaluate the inhibitory effect of ensartinib on CYP3A4 enzyme, results showed ensartinib moderately inhibited CYP3A4 activity in HepG2-CYP3A4 cells Cancers (Basel). 2020 Mar 28;12(4):813.
MDCKII-ABCC1 >50 µM 10 min Evaluate the inhibitory effect of ensartinib on ABCC1 transporter, results showed ensartinib had insignificant inhibition on ABCC1-mediated calcein AM efflux Cancers (Basel). 2020 Mar 28;12(4):813.
MDCKII-ABCG2 9.13 µM 10 min Evaluate the inhibitory effect of ensartinib on ABCG2 transporter, results showed ensartinib significantly inhibited ABCG2-mediated hoechst 33342 efflux Cancers (Basel). 2020 Mar 28;12(4):813.
MDCKII-ABCB1 3.69 µM 10 min Evaluate the inhibitory effect of ensartinib on ABCB1 transporter, results showed ensartinib significantly inhibited ABCB1-mediated hoechst 33342 efflux Cancers (Basel). 2020 Mar 28;12(4):813.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J male mice Drug-induced hepatotoxicity model Gavage 60 mg/kg or 120 mg/kg Once daily for 4 weeks To evaluate the hepatotoxic effects of Ensartinib in vivo. Results showed that Ensartinib significantly increased serum ALT, AST, and ALP levels and induced hepatocyte apoptosis and fibrosis. Cell Biol Toxicol. 2024 May 24;40(1):38.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.67mL

0.33mL

0.17mL

8.36mL

1.67mL

0.84mL

16.73mL

3.35mL

1.67mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
 

Historical Records

Categories